{"id":22052,"date":"2022-08-25T08:30:01","date_gmt":"2022-08-25T06:30:01","guid":{"rendered":"https:\/\/idibell.cat\/?p=22052"},"modified":"2022-08-25T11:58:47","modified_gmt":"2022-08-25T09:58:47","slug":"un-nou-test-de-deteccio-de-cancer-dendometri-que-es-pot-realitzar-a-casa","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2022\/08\/un-nou-test-de-deteccio-de-cancer-dendometri-que-es-pot-realitzar-a-casa\/","title":{"rendered":"Un nou test de detecci\u00f3 de c\u00e0ncer d\u2019endometri que es pot realitzar a casa"},"content":{"rendered":"

Investigadors de l’Institut d’Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL<\/a>), l’Institut Catal\u00e0 d’Oncologia (ICO<\/a>) i la Universitat d’Innsbruck a \u00c0ustria han dissenyat i provat un nou sistema no invasiu i d’automostra que podria avan\u00e7ar un any el diagn\u00f2stic del c\u00e0ncer d’endometri.<\/p>\n

El nou m\u00e8tode consisteix en un test epigen\u00e8tic que mesura el nivell de metilaci\u00f3 de dos gens concrets en mostres de citologies de c\u00e8rvix. Les metilacions son modificacions de l\u2019ADN que permeten activar o inactivar l\u2019expressi\u00f3 de gens. Les mostres es poden obtenir a trav\u00e9s de lleugers raspats del coll de l’\u00fater a la consulta, o a trav\u00e9s d’un petit dispositiu similar a un tamp\u00f3 que la pacient pot utilitzar a casa seva<\/strong>.<\/p>\n

Els resultats publicats a la revista Journal of Clinical Oncology<\/em><\/a> mostren que, en funci\u00f3 del sistema usat per obtenir la mostra, aquesta nova estrat\u00e8gia detecta entre el 90 i el 100% dels casos<\/strong> de c\u00e0ncer d’endometri.<\/p>\n

Segon Dra. Laura Costas<\/strong>, l\u00edder del projecte i investigadora principal del grup d’infeccions i c\u00e0ncer de l’IDIBELL i l’Institut Catal\u00e0 d’Oncologia, seria factible utilitzar aquest m\u00e8tode per a diagnosticar el c\u00e0ncer d\u2019endometri en poblacions de risc.<\/p>\n

\u00a0<\/strong><\/p>\n

El diagn\u00f2stic preco\u00e7, la clau per a la superviv\u00e8ncia<\/h3>\n

El c\u00e0ncer d’endometri \u00e9s un dels m\u00e9s freq\u00fcents entre les dones, afecta m\u00e9s de 400.000 dones l\u2019any mundialment. Actualment, els m\u00e8todes de diagn\u00f2stic s\u00f3n molt invasius i dolorosos, majorit\u00e0riament a trav\u00e9s de bi\u00f2psies de l’endometri. Un retard en el diagn\u00f2stic obliga a utilitzar tractaments m\u00e9s agressius i disminueix significativament la superviv\u00e8ncia de les pacients.<\/p>\n

“Aquest test ha funcionat b\u00e9 tant en les mostres que pren el personal m\u00e8dic a consulta com en automostres vaginals preses per la pacient a casa<\/em> -comenta la Dra. Costas<\/strong>-. Amb aquest nou sistema es pot reduir la pressi\u00f3 assistencial i la necessitat d’una derivaci\u00f3 inicial a un especialista i contribuir per tant a un diagn\u00f2stic m\u00e9s r\u00e0pid<\/em>.\u201d<\/p>\n

 <\/p>\n

Nou m\u00e8tode de diagn\u00f2stic per grups de risc<\/h3>\n

Aquest ha estat un estudi multidisciplinari en el qual s’han incl\u00f2s cohorts molt diverses per avaluar en profunditat el potencial de la nova metodologia.<\/p>\n

L’estrat\u00e8gia \u00a0pot ser molt beneficiosa en dos grups de risc<\/strong>: dones postmenop\u00e0usiques amb sagnat ginecol\u00f2gic, principal s\u00edmptoma del c\u00e0ncer d’endometri; i, dones amb la s\u00edndrome de Lynch, una afectaci\u00f3 gen\u00e8tica heredit\u00e0ria que predisposa a desenvolupar c\u00e0ncer. Els investigadors proposen realitzar estudis de cost-efectivitat i analitzar cohorts grans d\u2019aquests grups de risc de c\u00e0ncer d’endometri abans d\u2019implantar aquest nou m\u00e8tode de diagn\u00f2stic.<\/p>\n

Per altra banda, l’estudi ha mostrat resultats molt esperan\u00e7adors sobre la utilitat d’aquest m\u00e8tode en la poblaci\u00f3 general, fora de risc, ja que tamb\u00e9 ha perm\u00e8s identificar aquest c\u00e0ncer un any abans del seu diagn\u00f2stic. De cara al futur, s\u2019estan fent proves per avaluar tests similars per el diagn\u00f2stic d\u2019altres c\u00e0ncers ginecol\u00f2gics.<\/p>\n

L’estudi ha comptat tamb\u00e9 amb la participaci\u00f3 del Departament de Patologia i de Ginecologia del Hospital Universitari de Bellvitge.<\/p>\n

 <\/p>\n

 <\/p>\n

L\u2019Institut d’Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l’Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l’Institut Catal\u00e0 de la Salut, l’Institut Catal\u00e0 d’Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n

L\u2019IDIBELL \u00e9s membre del Campus d’Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L’any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Es tracta d’un test epigen\u00e8tic que \u00e9s capa\u00e7 de detectar entre el 90 i el 100% dels casos de c\u00e0ncer d’endometri. Aquest nou m\u00e8tode r\u00e0pid i no invasiu es pot realitzar tant en mostres de citologia de coll d’\u00fater obtingudes a la consulta m\u00e8dica com en automostres vaginals recollides a casa.<\/p>\n","protected":false},"author":8,"featured_media":22053,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[332,337,454],"tags":[],"class_list":["post-22052","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-infeccions-i-cancer","category-p-depidemiologia-salut-publica-prevencio-del-cancer-i-cures-palliatives"],"publishpress_future_action":{"enabled":false,"date":"2024-11-04 00:29:34","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/22052"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=22052"}],"version-history":[{"count":4,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/22052\/revisions"}],"predecessor-version":[{"id":22084,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/22052\/revisions\/22084"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/22053"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=22052"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=22052"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=22052"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}